Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Halozyme Therapeutics Inc (NASDAQ: HALO) closed at $68.95 up 0.12% from its previous closing price of $68.87. In other words, the price has increased by $0.12 from its previous closing price. On the day, 0.95 million shares were traded. HALO stock price reached its highest trading level at $69.48 during the session, while it also had its lowest trading level at $68.27.
Ratios:
For a deeper understanding of Halozyme Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.55 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.46. For the most recent quarter (mrq), Quick Ratio is recorded 1.37 and its Current Ratio is at 1.59. In the meantime, Its Debt-to-Equity ratio is 3.00 whereas as Long-Term Debt/Eq ratio is at 1.59.
On October 14, 2025, Leerink Partners Upgraded its rating to Market Perform which previously was Underperform but kept the price unchanged to $70.
Morgan Stanley Upgraded its Equal-Weight to Overweight on August 06, 2025, while the target price for the stock was maintained at $75.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 01 ’25 when Caudill Cortney sold 4,263 shares for $65.19 per share. The transaction valued at 277,905 led to the insider holds 12,737 shares of the business.
Connaughton Bernadette sold 829 shares of HALO for $59,356 on Dec 01 ’25. The Director now owns 42,123 shares after completing the transaction at $71.60 per share. On Dec 01 ’25, another insider, Torley Helen, who serves as the PRESIDENT AND CEO of the company, sold 16,569 shares for $68.92 each. As a result, the insider received 1,141,925 and left with 708,719 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 8108312576 and an Enterprise Value of 8945208320. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 14.49, and their Forward P/E ratio for the next fiscal year is 8.44. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.26. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.52 while its Price-to-Book (P/B) ratio in mrq is 16.08. Its current Enterprise Value per Revenue stands at 7.197 whereas that against EBITDA is 10.999.
Stock Price History:
The Beta on a monthly basis for HALO is 0.94, which has changed by 0.44049358 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, HALO has reached a high of $79.50, while it has fallen to a 52-week low of $47.50. The 50-Day Moving Average of the stock is 2.55%, while the 200-Day Moving Average is calculated to be 8.45%.
Shares Statistics:
For the past three months, HALO has traded an average of 2.27M shares per day and 2035150 over the past ten days. A total of 117.52M shares are outstanding, with a floating share count of 116.27M. Insiders hold about 1.13% of the company’s shares, while institutions hold 103.05% stake in the company. Shares short for HALO as of 1765756800 were 12500858 with a Short Ratio of 5.50, compared to 1763078400 on 12479411. Therefore, it implies a Short% of Shares Outstanding of 12500858 and a Short% of Float of 14.81.
